Real-world polypharmacy and healthcare resource utilization after early-line treatment with cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

Challenge

Patients with treatment-resistant epilepsy initiating cannabidiol (CBD) therapy often remain on multiple antiseizure medications, but the real-world impact of CBD on polypharmacy burden and healthcare resource utilization had not been characterized beyond clinical trials.

Solution

Target RWE researchers analyzed real-world data from early-line CBD-treated epilepsy patients to characterize changes in ASM polypharmacy and healthcare resource utilization following CBD initiation, funded by Jazz Pharmaceuticals.